

were randomly assigned to vaccinate and nonvaccinate groups. The vaccinate group received a modified live BVDV vaccine (Respanceine® BVD). Post vaccination titers were collected two weeks after vaccination. All cows delivered a live, healthy calf. Samples for BVDV serology and virus isolation were collected from the calves at birth, prior to colostrum intake, and again at 36-48 hours of age. Samples for BVDV serology and virus isolation, and a colostrum sample were collected

from the cows prior to the calf suckling. One of the calves from the nonvaccinate group had BVDV present at birth on virus isolation. This was confirmed at necropsy 3 months later. All cows had high titers both pre- and post-vaccination. Colostrum titers for BVDV from all cows were high. Variable BVDV titers were found in the calves. The statistical analysis is not complete, but will be prior to presentation.

## Evaluation of Type II Killed BVD Vaccine in the Face of Type II BVD Challenge

**Donna M. Gatewood, DVM, MS**

**W. Charles Ohnesorge**

**Carol A. Spillers**

**Benjamin P. All**

*Diamond Animal Health*

*2538 SE 43rd Street*

*Des Moines, Iowa 50317*

Type II BVD continues to be a concern for cattle producers. Type I MLV BVD vaccines reportedly provide adequate protection against disease caused by Type II BVD. However, MLV vaccines cannot be used in all management situations. This study was designed to test the efficacy of an experimental killed Type II BVD vaccine. In addition, the study compared results with efficacy of modified live and killed Type I BVD vaccines, as well as with efficacy of a killed Type II/MLV Type I combination.

Cattle (n=30) that were seronegative against BVD (SN<1:2) were divided into five test groups of six animals each. On days 0 and 14, cattle were bled and vaccinated with one of the following preparations: **1)** MLV Type I BVD vaccine. This vaccine was prepared according to the current outline of production for MLV BVD vaccine. Product was reconstituted and administered according to the label directions at the time of use. **2)** Killed Type I BVD vaccine. This vaccine was prepared according to the current outline of production for KBVD vaccine. Product was administered according to the label directions. **3)** Killed Type II BVD vaccine. This vaccine was prepared and formulated according to the current outline of production for KBVD vaccine **except** that Type II BVD Strain 125 (NVSL, Ames, Iowa) was used in place of strain C24V. 9CFR final product release tests were performed on the final product. Animals were inoculated with 2 ml of the preparation contain-

ing no less than 6.5 logs of Type II Killed BVD virus per dose. **4)** Killed Type I BVD/MLV Type II BVD vaccine. MLV Type I BVD vaccine was reconstituted with the killed type II BVD vaccine described in 3). **5)** RPMI 1640 (untreated control).

Calves were bled on days 21 and on day of challenge. Calves from each group were challenged with Type II BVD (BVD CHV, "890" 94-9, 11/94, NVSL, Ames, Iowa) according to the NVSL Type II challenge protocol on day 28. After challenge, animals were observed daily. Daily rectal temperatures were obtained and clinical signs were scored according to the Diamond Animal Health Carlisle Research Facility scoring key. Daily nasal swabs were taken for virus isolation. Additional serum samples were collected 7 and 14 days after challenge. All serum samples were assayed for the presence of both Type I and Type II BVD-neutralizing antibodies.

Data from clinical scores, viral shedding and serum neutralization studies were statistically evaluated to determine the relative efficacies of the different vaccines. Results showed that the killed Type II, the MLV Type I, and the killed Type II/MLV Type I combination vaccines were effective in protecting calves from Type II BVD challenge, while the killed Type I vaccine was not. Serum neutralization titers suggested that the killed Type II vaccine might confer longer duration of immunity than the MLV Type I vaccine.


# VISION<sup>®</sup> IS PROFIT

BLACKLEG VACCINES




© Copyright American Association of Bovine Practitioners; open access distribution.

Vision<sup>®</sup> 7 Weaning Weight Comparisons  
5 Herds, 1018 Calf Pairs  
10.4 pounds per calf advantage (avg. all calves)



Feed Consumption Comparison  
lbs. of feed/head before and after administration



\*Field trial reports available upon request.  
\*\*Blackleg<sup>®</sup> 7 vaccine

These days in the cattle business, anything that's not working for you is costing you money. Unless your blackleg vaccine is Vision<sup>®</sup>, chances are you're not seeing the profits that are possible.

Cattlemen that use Vision 2 mL vaccines know there is a PROFIT difference, from the ranch to the rail. They get the effective protection of Vision and fewer injection site reactions. PROFIT is fewer injection site

reactions. Less stress on animals, weaning weight and feed consumption increase, feed conversion improves, and fewer injection site "knots" occur.\* PROFIT is fewer "knots" because discounts at the auction market and carcass trim from injection site blemishes are avoided. See the PROFITS for yourself.

When it comes to the bottom line, VISION is PROFIT.

Vision<sup>®</sup> 7, Vision<sup>®</sup> 8, Vision<sup>®</sup> 7 Somnus, Vision<sup>®</sup> CD and Vision<sup>®</sup> CD•T vaccines.



2 mL  
VISION<sup>®</sup> VACCINES  
See the profits.™



Bayer Corporation, Agriculture Division, Animal Health, Shawnee Mission, Kansas 66201

©1996, Bayer Corporation